Measuring the return from pharmaceutical innovation 2019
The past decade has seen increasing pressures undermine the productivity of biopharma R&D, leading to a decade of decline in the return on investment. At the same time, innovative new treatments are changing the face of disease management. New treatment modalities and an increasing understanding of precision medicine have led to the need for new R&D models and a future where medicine is more participatory, preventative and personalised.
Видео Measuring the return from pharmaceutical innovation 2019 канала Deloitte Switzerland
Видео Measuring the return from pharmaceutical innovation 2019 канала Deloitte Switzerland
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Deloitte swissVR II/2018 interview015 Dynamik und Agilität in der Berufswelt - Teil 1 - Interview mit Hans Werner (Swisscom)Deloitte Company Triathlon 2019Deloitte HealthConnect webcast 29 November 2020AI and ML explained... in under 100 wordsThe Deloitte Wealth Management Centre Ranking 2015Digitalisation and innovation in the Swiss public sector in 2021: where are the opportunities?IPO Key considerations with Liam BaynesTaking healthcare out of its clinical settingTeo - Audit and assurance technologyWarum Personal Branding das neue Corporate Branding ist (Folge 069)Never stop growing #deloitte #talentRPA SupplyChainUS tax challenges and how to handle themThe Deloitte DevOps LandscapeVerkaufsautomaten – vernetzt, intelligent und persönlich (Folge 122)Der Weg zum digitalen Wandel im öffentlichen Sektor - Rolf Bruegger InterviewIPO series introduction by Patrick ShelleyConquering views and multicultural trainingTeam spirit and sustainable facility services